Capsaicin (Qutenza®)

Assessment Status Rapid Review complete
Drug Capsaicin
Brand Qutenza®
Indication Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.
Assessment Process
Rapid review commissioned 15/06/2012
Rapid review completed 28/06/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.